⋮
0
0
Chugai’s ALK Inhibitor “Alecensa®” Approved for the Treatment of First Line Therapy on ALK-Positive Non-Small Cell Lung Cancer in the US
Showing live article 866 of 3352 in channel 19681208
Article Details:
Author:
Language: Japanese
Channel Number: 19681208
Article Number: 866
Date: November 7, 2017, 1:00 pm
URL: http://www.qlifepro.com/press/20171108-15-32680/chugai-pharmaceutical-8/
GUID: http://www.qlifepro.com/press/?p=32680
←
$
..going to article 866
X
X
NSFW?
Claim
0
X
Mark channel Not-Safe-For-Work?
cancel
confirm
NSFW Votes:
(
0
votes)
X
Are you the publisher?
Claim
or
contact us about
this channel.
X
No ratings yet.
X
RSSing.com
Search
Sharing:
Title:
URL:
Copy Share URL